Relative Effectiveness of Talquetamab Versus Real-World Physician's Choice Treatment Regimens in Patients With...

Talquetamab is approved for treatment of triple-class exposed relapsed/refractory multiple myeloma (RRMM) based on the MonumenTAL-1 study (NCT03399799/NCT04634552). Previous indirect treatment comparisons (ITCs) demonstrated superiority of talquetamab over real-world physician's choice (RW) treatment regimens. Here, we report an updated ITC with an additional ∼ 8 and 15 months of follow-up in MonumenTAL-1 and the Flatiron Health Research Database, respectively.

The research database was used to develop an external control arm for patients who met key MonumenTAL-1 eligibility criteria (n = 629; 1169 eligible lines of therapy [LOT]). Patient-level data from MonumenTAL-1 were included for patients who received talquetamab 0.4 mg/kg QW (n = 143) or 0.8 mg/kg Q2W (n = 154). After adjusting for baseline imbalances, the relative effectiveness of talquetamab versus RW treatment regimens was assessed for progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS).

Talquetamab 0.4 mg/kg QW and 0.8 mg/kg Q2W, respectively, demonstrated significant improvements over RW treatment regimens for all outcomes, including PFS (HR, 0.66 [95% CI, 0.53-0.82] and 0.54 [0.44-0.68]), TTNT (HR, 0.57 [0.47-0.69] and 0.49 [0.40-0.60]), and OS (HR, 0.56 [0.42-0.74] and 0.42 [0.31-0.57]); superiority was maintained in the United States Prescribing Information-aligned subgroup of patients with ≥ 4 prior LOT. Results from sensitivity analyses were generally similar.

Talquetamab demonstrated continued superiority over RW treatment regimens in RRMM for PFS, TTNT, and OS, including in patients with ≥ 4 prior LOT. These data suggest talquetamab is an effective treatment option in eligible patients.